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Deranged protein metabolism is known to complicate
uremia. Insulin resistance is evident in chronic hemodialysis
(CHD) patients. We hypothesized that the degree of insulin
resistance would predict protein catabolism in non-diabetic
CHD patients. We examined the relationship between
Homeostasis Model Assessment (HOMA) and fasting
whole-body and skeletal muscle protein turnover in 18
non-diabetic CHD patients using primed-constant infusions
of L-(1-13C) leucine and L-(ring-2H5) phenylalanine. Mean7s.d.
fasting glucose and body mass index were 80.679.8 mg/dl
and 25.474.4 kg/m2, respectively. Median (interquartile
range) HOMA was 1.6 (1.4, 3.9). Mean7s.e.m. skeletal muscle
protein synthesis, breakdown, and net balance were
89.57711.67, 97.02713.3, and 7.4477.14 lg/100 ml/min,
respectively. Using linear regression, a positive correlation
was observed between HOMA and skeletal muscle protein
synthesis (R2¼ 0.28; P¼ 0.024), and breakdown (R2¼ 0.49;
P¼ 0.001). An inverse association between net skeletal
muscle protein balance and HOMA was also noted (R2¼ 0.20;
P¼ 0.066). After adjustment for C-reactive protein, only the
relationship between HOMA and skeletal muscle protein
breakdown persisted (R2¼ 0.49; P¼ 0.006). There were no
significant associations between components of whole-body
protein turnover and HOMA. This study demonstrates that
insulin resistance is evident in non-diabetic dialysis patients,
is associated with skeletal muscle protein breakdown, and
represents a novel target for intervention in uremic wasting.
Kidney International (2007) 71, 146–152. doi:10.1038/sj.ki.5001984;
published online 25 October 2006
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A decline in lean body mass and its precipitant sarcopenia
continue to challenge those attempting to avert uremic
wasting in patients with end-stage renal disease (ESRD).1,2 In
addition to its epidemiologic association with worsened
clinical outcomes,3–8 recent evidence suggests that deranged
protein catabolism itself may directly impair endothelial
function,9 increase oxidative stress burden,10,11 and weaken
the immune response.6,12 Postulated to underlie this
imbalance between protein accretion and breakdown include
contributions from metabolic acidosis,13,14 the dialysis
procedure itself,15–18 chronic inflammation,19–21 and hormo-
nal imbalances.22–24
Recently, our group has reported that poorly controlled
diabetes mellitus is a potent-independent predictor for the
loss of lean body mass in chronic dialysis patients through
increased skeletal muscle protein breakdown.25,26 Similarly,
Chevalier et al.27 has demonstrated insulin resistance and
enhanced whole-body protein catabolism in relatively young
healthy obese women compared to lean women during the
post-absorptive state. Taken together, these observations
suggest resistance to the anti-catabolic effects of insulin as a
possible mechanism underlying the muscle wasting seen in
several disease states.
In this study, we hypothesized that the extent of insulin
resistance in ESRD would be a determinant of the degree of
protein breakdown, especially at the muscle metabolism level.
In order to test this hypothesis, we examined the relationship
between insulin resistance, as measured by Homeostasis
Model Assessment (HOMA), and fasting protein turnover
(whole body and skeletal muscle) in 18 non-diabetic chronic
hemodialysis (CHD) patients, using a primed-constant
infusion of L-(1-13C) leucine and L-(ring-2H5) phenylalanine.
RESULTS
Demographics, body composition, and nutritional markers
Table 1 depicts the demographic characteristics, body
composition, and baseline fasting nutritional parameters of
the 18 patients included in the study. Two-thirds of the
population were men and the majority were African-
American (n¼ 14; 78%). The most common etiologies of
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ESRD were hypertension (n¼ 11; 61%) and focal segmental
glomerulosclerosis (n¼ 4; 22%). The mean7s.d. age and
vintage were 47.7714.6 and 6.374.3 years, respectively.
Overall, the study population consisted of non-obese
subjects with a mean7s.d. body weight and body mass index
(BMI) of 73.3715.3 kg and 25.474.4 kg/m2, respectively. Fat
mass percentage as measured by dual-energy X-ray absorp-
tiometry was 30.8710.3%. Median (interquartile range)
normalized protein catabolic rate was 0.8 (0.7, 1.1) g/kg/day
within a month of the study protocol and mean serum
albumin concentration was 3.670.4 g/dl. Median C-reactive
protein (CRP) was 5.8 mg/l (2.0, 9.4). As patients with
impaired glucose tolerance (fasting blood glucose X100 mg/
dl) were also excluded, the cohort demonstrated good
glycemic control with a mean fasting plasma glucose of
80.679.8 mg/dl.
Despite exclusion of patients with diabetes mellitus and
severe obesity (BMI435), the median (interquartile range)
HOMA score was 1.6 (1.4, 3.9). Of the limited parameters
examined in this study (age, CRP, intact parathyroid
hormone, and BMI), only BMI was significantly associated
with HOMA score on univariate analysis (r¼ 0.54,
P¼ 0.022).
Forearm muscle protein metabolism
The mean7s.e.m. values for skeletal muscle protein synth-
esis, breakdown, and balance for the study subjects were
89.57711.67, 97.02713.37, and 7.4477.14 mg/100 ml/
min, respectively (Table 2). These values were consistent
with previously published results from our laboratory.25
Using simple linear regression analysis, the slope of the
regression line between HOMA score and muscle protein
synthesis (b) was significantly greater than zero, indicating
that muscle protein synthesis tended to increase as HOMA
score increased (b¼ 18.42; 95% confidence inter-
val¼ 2.79–34.05; P¼ 0.024; R2¼ 0.28; Figure 1a). Compared
to synthesis, the slope of the regression line was larger for
skeletal muscle breakdown indicating an even stronger
association with HOMA score (b¼ 27.84; 95% confidence
interval¼ 12.72–42.95; P¼ 0.001; R2¼ 0.49; Figure 1b). This
resulted in an inverse relationship between HOMA and
muscle protein balance, which approached statistical sig-
nificance (b¼9.42; 95% confidence interval¼19.53 to
0.69; P¼ 0.066; R2¼ 0.20; Figure 1c). After adjusting for
CRP, only muscle protein breakdown remained significantly
associated with HOMA score (b¼ 27.88; 95% confidence
interval¼ 12.24–43.53; P¼ 0.006). Similar results were found
after adjustment for fat mass (data not shown).
Whole-body protein metabolism
Table 3 depicts the results for whole-body protein metabo-
lism components expressed as mg/kg fat-free mass/min. The
mean7s.e.m. for synthesis, breakdown, and net balance were
3.9470.30, 3.8670.14, and 0.0870.26 mg/kg fat-free
mass/min, respectively. There were no statistically significant
associations between HOMA and the components of whole-
body protein turnover before and after adjustment for CRP.
DISCUSSION
Multiple in vitro and in vivo studies have demonstrated the
anabolic effects of insulin beyond simple carbohydrate
Table 1 | Baseline demographic, nutritional, and biochemical
characteristics
Demographics N=18
Gender (% males) 12 (67%)
Race (% AA) 14 (78%)
Age (years) 47.7714.6
Etiology of ESRD (%)
Glomerulonephropathy 5 (28%)
FSGS 4 (22%)
IgA nephropathy 1 (6%)
Hypertension 11 (61%)
Polycystic kidney disease 2 (11%)
Duration of hemodialysis (years) 6.374.3
Body weight (kg) 73.3715.3
BMI (kg/m2 ) 25.474.4
Fat mass by DEXA (%) 30.8710.3
Blood chemistries
Serum albumin (g/dl) 3.670.4
Serum prealbumin (mg/dl) 30.2710.2
Serum transferrin (mg/dl) 144.5752.9
Blood urea nitrogen (mg/dl) 45.7718.2
Serum creatinine (mg/dl) 10.273.5
Hct (%) 37.3 (35.4, 42.2)
Serum CRP (mg/l) 5.8 (2.0, 9.4)
n-PCR (g/kg/day) 0.8 (0.7, 1.1)
Plasma glucose (mg/dl) 80.679.8
HOMA 1.6 (1.4, 3.9)
Plasma metabolic hormones
Insulin (mU/ml) 8.5 (6.0, 18.7)
Glucagon (ng/l) 190.5 (137.2, 259.4)
Growth hormone (ng/ml) 0.6 (0.3, 1.8)
IGF-1 (ng/ml) 161.1778.2
Cortisol (mg/dl) 12.374.3
Epinephrine (pg/ml) 43.6724.0
Norepinephrine (pg/ml) 641.67402.2
AA, African-American; BMI, body mass index; CRP, C-reactive protein; DEXA, dual-
energy X-ray absorptiometry; ESRD, end-stage renal disease; FSGS, focal segmental
glomerulosclerosis; HOMA, homeostasis model assessment; IGF, insulin-like growth
factor; IgA, immunoglobulin A; n-PCR, normalized protein-catabolic rate.
Values are presented as mean7s.d. for normally distributed data, median and (IQR)
for non-normally distributed data, and percentages as appropriate.
Table 2 | Association between HOMA and skeletal muscle
protein turnover
Component
(lg/100 ml/
min) Mean7s.e.m. b R2 95% CI Significance
Synthesis 89.57711.67 18.42 0.28 2.79–34.05 P=0.024*
Breakdown 97.02713.37 27.84 0.49 12.72–42.95 P=0.001*
Balance 7.4477.14 9.42 0.20 19.53–0.69 P=0.066
CI, confidence interval; HOMA, homeostasis model assessment; s.e.m., standard error
of mean.
Skeletal muscle protein components were expressed as mean7s.e.m. Also
presented are the b, r2, and 95% CIs for the simple linear regression performed
between components of muscle protein turnover and HOMA score.
*Statistically significant association Po0.05.
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metabolism.28 The earliest observations of the insulinopenic
condition in humans (i.e. uncontrolled Type 1 diabetes
mellitus) were hallmarked by negative nitrogen balance, lean
tissue atrophy, and hyperaminoacidemia.28,29 The underlying
mechanism demonstrated by Mitch et al. appears to be
suppression of insulin receptor substrate-1-associated
phosphatidylinositol 3-kinase activity resulting in stimula-
tion of the ubiquitin-proteasome proteolytic system via
caspase-3.30,31 Investigations using tracer kinetic models and
insulin clamp techniques in healthy individuals have detailed
that it remains the blunting of proteolysis rather than
enhanced protein synthesis that belies the net protein
anabolic effect of insulin in the post-absorptive state.32–35
Our laboratory recently reported that the presence of
Type 2 diabetes mellitus in CHD patients predicts increased
skeletal muscle protein breakdown and loss of lean body mass
compared to matched non-diabetic CHD controls, suggesting
that the above findings apply not only to insulin-deficient
states, but insulin-resistant ones as well.25,26 Consistent with
these observations, Chevalier et al.27 recently demonstrated a
greater degree of fasting whole-body protein breakdown and a
suppressed anabolic response to insulin in relatively healthy
obese women compared to their lean counterparts under-
going hyperinsulinemic, euglycemic, isoaminoacidemic clamp
studies. Furthermore, the metabolic response to insulin in
carbohydrate metabolism has been shown to be impaired with
varying degrees of uremia.36–39 Although the etiology of this
impairment has not been fully elucidated, our limited analysis
indicates that BMI is an important factor, as has been shown
in the general population. Based on these observations, we
hypothesized that insulin resistance significantly contributes
to the enhanced muscle protein catabolism observed in CHD
patients. Our results indicate that in the absence of frank
glucose intolerance (fasting blood glucose X100 mg/dl) or
severe obesity (BMI435), insulin resistance is evident in the
dialysis population and is associated with increased skeletal
muscle protein breakdown, a relationship that persists even
after adjustment for inflammation.
An interesting observation from this study was that the
association between insulin resistance and protein breakdown
remained significant only for the muscle data and not for
whole-body protein turnover as previously observed in obese
subjects with insulin resistance.27 The lack of a significant
association with whole-body protein turnover could be related
to several factors, including but not limited to the differences
in patient populations. In contrast to Chevalier et al., who
studied young and otherwise healthy women with centripetal
obesity where visceral fat mass burden may have contributed
to their findings, we focused on a relatively non-obese older
ESRD cohort where factors including acidosis, inflammation,
and dialysis itself are known to influence visceral protein
stores. In this setting, it remains possible that the insulin-
mediated anabolic actions on protein turnover may be
occurring predominately at the skeletal muscle compartment.
Furthermore, the use of concomitant substrate administration
via dual-clamp procedure in the former study may have
influenced measurement of both insulin resistance and
protein turnover, whereas our study examined these dynamics
exclusively during the post-absorptive state.
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Figure 1 | Scatter plots of HOMA versus skeletal muscle protein
metabolism components. Simple linear regression revealed a direct
relationship between HOMA and (a) skeletal muscle protein synthesis
(P¼ 0.024) and (b) skeletal muscle protein breakdown (P¼ 0.001).
(c) An inverse relationship between HOMA and net muscle protein
balance was observed that approached significance (P¼ 0.066).
*Statistical significance Po0.05.
Table 3 | Association between HOMA and whole-body protein
turnover
Component
(mg/kg
FFM/min) Mean7s.e.m. b R2 95% CI Significance
Synthesis 3.9470.30 0.06 0.004 0.54–0.42 P=0.803
Breakdown 3.8670.14 0.02 0.002 0.20–0.23 P=0.870
Balance 0.0870.26 0.08 0.010 0.49–0.33 P=0.699
CI, confidence interval; FFM, fat-free mass; HOMA, homeostasis model assessment;
s.e.m., standard error of mean.
Whole-body protein components were expressed as mean7s.e.m. Also presented
are the b, r2, and 95% CIs for the simple linear regression performed between
components of protein turnover and HOMA score.
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Our results also indicated a weak correlation between
HOMA score and protein synthesis. Studies have shown that
in the post-absorptive state, the protein metabolic effects of
insulin are chiefly to suppress proteolysis resulting in
diminished substrate availability for protein synthesis.32,33,40
However, provision of amino acids appears to largely reverse
this relative depression in amino-acid synthesis, at least at the
whole-body level.15,27 This suggests that both components of
protein turnover, synthesis and breakdown, are dynamic and
not mutually exclusive. This may reflect an imperfect
adaptive mechanism to preserve somatic protein stores in
diseases marked by enhanced catabolism and provide a
possible explanation of our findings.
Although intriguing, these results should be interpreted
with the following caveats. First, the cross-sectional nature of
the design reveals only an association between insulin
resistance and skeletal muscle protein homeostasis. Tests of
causality addressing the effect of modifiers of insulin
resistance as well as the hormone itself on skeletal muscle
protein dynamics should be pursued. Towards that end, Wang
et al.41 have recently elegantly demonstrated in an animal
model that the enhanced muscle proteolysis associated with
insulin resistance appears to be reversible with the adminis-
tration of the peroxisome proliferator-activated receptor-g
agonist Rosiglitazone.41 These results need to be extended to
human studies. The demographics of our study population
also reflect a disproportionately high percentage of African-
American subjects, which may limit the applicability of our
findings to the general dialysis population. Finally, we
recognize the limitations of sample size, specifically with
respect to our ability to adjust for multiple potential
confounders. Although the association between HOMA and
protein breakdown persisted both before and after adjustment
for CRP, the potential for over-fitting within our model of 18
patients exists. However, the extensive nature of the protocol
precludes recruitment of subjects on a large scale and we
believe this study to be among the largest of its kind.
In conclusion, it has been observed that CHD patients are
at risk for a progressive loss in lean body mass not entirely
accounted for by inadequate nutrient intake alone.31,42,43
Given the high prevalence of protein cachexia and its
unequivocal association with adverse clinical outcomes, the
identification of modifiable contributors is of paramount
importance. Moreover, the direct effects of dysregulated
protein catabolism have been recently shown to impair
endothelial function, indicating that the adverse effects of
uremic wasting extend beyond its nutritional aspects alone.9
As such, the results of this study indicate that insulin
resistance in ESRD may be an important contributor to
protein wasting that represents a novel target for intervention.
MATERIALS AND METHODS
Patients
Patients were recruited from the Vanderbilt University Outpatient
Dialysis Unit. Inclusion criteria for the study were patients who have
been on CHD therapy for at least 6 months, with less than 100 ml/
min of urine output, using a biocompatible hemodialysis membrane
(Fresenius F80, Fresenius USA, Lexington, MA, USA), receiving an
adequate dose of dialysis (double pool Kt/V X1.4), on a thrice-
weekly CHD program. Patients with a known history of diabetes
mellitus or impaired glucose tolerance defined as a fasting blood
glucose X100 mg/dl, BMI435, active infectious or inflammatory
disease (i.e. vascular access infections and overt periodontal disease),
hospitalization within the last 3 months before the study,
recirculation in the vascular access, and/or vascular access blood
flow less than 750 ml/min detected on the arteriovenous (AV) shunt,
and those receiving steroids and/or immunosuppressive agents were
excluded from the study. The Institutional Review Board of
Vanderbilt University approved the study protocol and written,
informed consent was obtained from patients before the study.
Patient characteristics are shown in Table 1.
Design
After reviewing the inclusion and exclusion criteria, 18 CHD
patients were included who underwent the study procedure.
Estimation of insulin resistance was performed by the HOMA
model, as follows: (plasma insulin (mU/ml) plasma glucose
(mmol/l))/22.5), which has been shown to correlate closely with
insulin sensitivity index as measured by hyperinsulinemic eu-
glycemic clamp in patients with varying degrees of renal failure.44
Within a week before each study, dual-energy X-ray absorptiometry
was performed on a non-dialysis day to measure lean and fat body
masses. Studies performing dual-energy X-ray absorptiometry
before and after dialysis suggest that there are minimal effects of
body-water changes on fat mass and bone measurements.45,46
Resting metabolic rate was measured via indirect calorimetry to
establish energy requirements before experimentation. Patients were
admitted to the General Clinical Research Center at approximately
1900 hours the prior evening, received a balanced meal from the
General Clinical Research Center bionutrition service, and remained
fasting after that.
A schematic diagram of the metabolic study day protocol is
depicted in Figure 2. Each metabolic study consisted of a 2 h
equilibration phase followed by a 30 min basal sampling phase. A
dialysis catheter was placed at the venous site of the AV shunt of the
forearm at 0600 hours to collect a baseline blood sample (to assess
baseline biochemical nutritional markers and isotopic backgrounds)
and then to initiate the isotope infusion. The arterial side of the AV
shunt was the site of choice used for sampling arterial blood. The
only occasion that would affect the arterial purity of the samples
would be if there were stenoses in the AV shunt causing the venous
blood to mix with arterial blood (recirculation). Therefore,
recirculation of the AV shunt as well as vascular access blood
flow to assess stenoses in the AV shunts was checked in every
patient before each study utilizing the ultrasound dilution technique
(Transonic Systems Inc., Ithaca, NY, USA). The venous site of
the AV shunt was used to infuse the isotopes. Another catheter
was placed in a deep vein (on a retrograde insertion) of the
contralateral forearm to sample blood draining from the forearm
muscle bed.
At the start of the experiment, subjects received a bolus injection
of NaH13CO3 (0.12 mg/kg), L-(1-
13C) leucine (7.2 mmol/kg), and
L-(ring-2H5) phenylalanine (7.2 mmol/kg) to prime the CO2, leucine,
and phenylalanine pools, respectively. A continuous infusion of
leucine (0.12 mmol/kg/min) and phenylalanine (0.12 mmol/kg/min)
isotopes was then started and continued throughout the remainder
of the study.
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Simultaneously with each blood sampling, breath samples were
collected from the subjects via a Douglas bag with duplicate 20 ml
samples placed into non-siliconized glass vacutainer tubes for
measurement of breath 13CO2 enrichment. Subjects were asked to
breathe through a mask for several breath cycles, each time blood
was collected. Forearm blood flow was estimated using capacitance
plethysmography (Model 2560 with URI/CP software version 3.0,
Moro Bay, CA, USA) during the equilibration phase. Specifically,
two blood pressure cuffs were placed on the subjects forearm
contralateral to the forearm with the AV shunt: one cuff 3 cm above
the antecubital fossa and another cuff on the wrist. The technique
involves abrupt interruption of venous outflow with a proximal cuff
inflated to above venous pressure, but below arterial pressure
(approximately 50 mmHg), which causes the volume of the limb to
increase owing to arterial inflow. A mercury strain gauge
plethysmograph is used to measure the volume change in the limb.
The rate of change of the volume, in percent per minute, is the
arterial flow rate at the moment of venous occlusion. This procedure
was repeated for at least five times or until five similar
measurements were obtained.
Analytical procedures
Blood samples were collected into Venoject tubes containing 15 mg
Na2-ethylenediaminetetraacetic acid (Terumo Medical Corp, Elkton,
MD, USA). A 3-ml aliquot of blood was transferred to a tube
containing ethylenediaminetetraacetic acid and reduced glutathione
with the plasma stored at 801C for later measurement of plasma
epinephrine and norepinephrine concentrations by high-perfor-
mance liquid chromatography.47 The remaining blood was spun in a
refrigerated (41C) centrifuge (Beckman Instruments, Fullerton, CA,
USA) at 3000 r.p.m. for 10 min and plasma was extracted and stored
at 801C for later analysis. Plasma glucose concentrations were
determined by the glucose oxidase method (Model II Glucose
Analyzer, Beckman Instruments, Fullerton, CA, USA).
Nutritional biochemical parameters were carried out at a
specialized ESRD clinical and special chemistry laboratory
(RenaLab, Richland, MS, USA). Serum albumin was analyzed using
bromcresol green technique. Serum prealbumin was analyzed by an
antigen–antibody complex assay and serum transferrin was analyzed
by turbidimetric reading (Hitachi 717, Boehringer Mannheim,
Indianapolis, IN, USA). CRP was measured using nephelometric
analysis at the Vanderbilt University Medical Center Clinical
Chemistry laboratory.
Plasma c-peptide and insulin were measured by a double-
antibody radioimmunoassay (Linco research Inc., St Charles, MO,
USA). Immunoreactive insulin was determined in plasma with a
double-antibody system. Plasma aliquots for glucagon determina-
tion were placed in tubes containing 25 kallikrein-inhibitor units of
aprotinin (Trasylol, FBA Pharmaceutical, New York, NY, USA) and
were later measured by established radioimmunoassay with a
double-antibody system modified from the method of Morgan
and Lazarow48 for insulin. Insulin and glucagon antisera and
standards, as well as (125I) labeled hormones, were obtained
from RL Gingerich (Linco Research, St Louis, MO, USA). Clinical
Assays Gammacoat Radioimmunoassay kit (Travenol-GenTech,
Cambridge, MA, USA) was used to measure plasma cortisol
concentrations. Plasma insulin-like growth factor-I concentrations
were determined by a radioimmunoassay acid-extraction procedure
(Nichols Institute Diagnostics, San Juan Capistrano, CA, USA).
Plasma amino-acid concentrations were determined by reversed-
phase high-performance liquid chromatography after derivatization
with phenyliosthiocynate.49
Plasma enrichments of (13C) leucine, (13C) ketoisocaproate
(KIC), and (ring-2H5) phenylalanine were determined using gas
chromatography/mass spectrometry (GC/MS-Hewlett-Packard
5890a GC and 5970 MS, San Fernando, CA, USA). Plasma was
deproteinized with 4% perchloric acid, and the supernatant was
passed over a cation exchange resin to separate the keto and amino
acids. The keto acids were further extracted with methylene chloride
and 0.5 M ammonium hydroxide.50 After drying under nitrogen gas,
keto and amino acids fractions were derivatized51 with N-methyl-N-
(t-butyldimethylsilyl)-trifluoroacetamide containing 1% t-butyl-
dimethylchlorosilane (MtBSTFAþ 1% t-BDMCS, Regis Technolo-
gies Inc., Morton Grove, IL, USA). The derivatized samples were
then analyzed with GC/MS for plasma leucine, phenylalanine, and
KIC enrichments using selected ion monitoring. The major
fragments analyzed for the tBDMCS derivative of KIC and 13C-
KIC were the (M-57) ion fragments 301 and 302 m/z, respectively.
The enrichment was quantified in plasma as the ratio of 13C-
KIC:KIC (ion abundance of 301/302 m/z). Enrichment measure-
ments were made in duplicate, and duplicates had a coefficient of
variation o3%. Breath 13CO2 was measured by isotope ratio mass
spectrometry (Metabolic Solutions, Nashua, NH, USA).52
Calculations
Net skeletal muscle protein balance (synthesis–breakdown) was
determined by dilution and enrichment of phenylalanine across the
forearm as described by Gelfand and Barrett.34 Because phenylala-
nine is neither synthesized de novo, nor metabolized by skeletal
muscle, rate of appearance (Ra) of unlabeled phenylalanine reflects
muscle protein breakdown, whereas the rate of disappearance (Rd)
of labeled phenylalanine estimates muscle protein synthesis.34
Phenylalanine Rd was calculated by multiplying the fractional
extraction of the labeled phenylalanine (based on plasma arterial
and venous phenylalanine enrichments and concentrations) by the
arterial phenylalanine concentration and normalized to forearm
blood flow measured by plethysmography (expressed as 100 ml/
min). Net phenylalanine Ra was calculated by subtracting the net AV
balance of phenylalanine across the extremity from the phenyl-
alanine Rd.34,53 Rates of skeletal muscle protein breakdown and net
synthesis were determined from the phenylalanine Rd and Ra,
 0 min
Equilibration
150120
Blood and breath samples 
135
Sampling
Primed-constant infusion of 
L-[1-13C] leucine and L-[2H5]phenylalanine
Metabolic cart Plethysmography
Figure 2 | Schematic diagram of the metabolic study day
protocol. Denotes time points for blood draws and breath sample
collections. Metabolic cart and plethysmography measurements were
performed once during the equilibration phase. A primed-constant
infusion of L-(1-13C) leucine and L-(ring-2H5) phenylalanine was
maintained throughout the entire study (150 min).
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assuming that 3.8% of skeletal muscle protein is comprised of
phenylalanine.
The steady-state rates of total whole-body leucine Ra were
calculated by dividing the (13C) leucine infusion rate by the plasma
(13C) KIC enrichment.53 Plasma KIC provides a better estimate of
intracellular leucine enrichment than does plasma leucine enrich-
ment, owing to the fact that KIC is derived from intracellular leucine
metabolism.53 Steady-state conditions for phenylalanine and CO2
(Figure 3) enrichments were achieved as evidenced by slopes within
each phase not significantly different than zero. Breath 13CO2
production was determined by multiplying the total CO2 produc-
tion rate by the breath 13CO2 enrichment.
53 The rate of whole-body
leucine oxidation was calculated by dividing breath 13CO2 produc-
tion by 0.8 (correction factor for the retention of 13CO2 in the
bicarbonate pool)54 and by the plasma KIC enrichment. The leucine
Rd, an estimate of whole-body protein synthesis, was determined
indirectly by subtracting leucine oxidation from total leucine Rd.
Rates of whole-body protein breakdown, amino-acid oxidation, and
protein synthesis were calculated from the endogenous leucine Ra,
the leucine oxidation rate, and the non-oxidative leucine Rd,
respectively, assuming that 7.8% of whole-body protein is comprised
of leucine.55
Rates of whole-body amino-acid oxidation were determined
from indirect calorimetry in combination with the leucine oxidation
data. The energy expended owing to amino-acid oxidation was
subtracted from the resting energy expenditure, and the net rates of
carbohydrate and lipid oxidation were calculated based on the non-
protein respiratory quotient.56 The assumptions and limitations of
calculating net substrate oxidation based on indirect calorimetry
measurements have been previously reviewed.56
Statistical analysis
Variables measured more than once during the study were averaged
for statistical analysis. Normally distributed continuous variables are
presented in the text and figures are presented as means7s.d. or
s.e.m., whereas non-normally distributed variables are presented as
medians and interquartile ranges. Spearman’s rank correlation
coefficient was used to determine the association between HOMA
and the following variables: age, BMI, intact parathyroid hormone,
and CRP. Linear regression was used to assess the relationship
between HOMA score and the continuous parameters of whole-
body and skeletal muscle protein turnover. Residual assumptions
were verified for these analyses. If residual analysis did not fulfill the
assumptions of normality, sensitivity analysis was performed with
transformation of the dependent variable which did not affect the
overall significance. The statistical software package SPSS 14.0
(Chicago, IL, USA) was used for analyses and two-sided P-values of
less than 0.05 were required to achieve statistical significance.
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